COMPUTER ASSISTED INTERACTIVE VIDEO DONOR SCREENING

主要目的是测试适用性、可接受性和 实施的商业可行性和进一步发展 交互式多媒体视频血液/血浆捐献者健康史系统 操作设置。这些目标将通过逐步融合来实现 将系统纳入捐赠和数据管理流程， 逐步增加系统的复杂性。预期效益 在以下方面有所改进： 1.筛查血液/血浆的操作系统的总体性能 献血者和收集血液制品，以及 2.血液和血浆供应的安全性。 成果将分阶段实现，首先是更新、测试和 并安装Talisman 1993年的试点测试独立系统。的 Talisman多媒体系统获得了有史以来第一个市场许可 1997年5月12日的监管机构。发展将按照 基于成本效益分析的SBIR第二阶段建设计划 在阶段I期间。第二阶段的暂定终点目标是 无纸化收集系统和增强的筛选功能 系统该计划的其他部分将涉及福利措施， 成本和开发符合生产法规的质量 系统该系统建成后将处理高达40%的血库 成本和60%的可报告错误。 拟议的商业应用： 美国每年有超过25，000，000例血液和血浆捐献， 四倍于这个市场的全球范围内，这取决于如何潜力 实施者重视利益，该系统可能价值数千万美元， 美元如果系统成功阻止了一次捐赠 最终导致产品召回， 制造商的价值可能超过100万美元。

Principal aims are to test the applicability, acceptability and commercial feasibility of implementation and further development of an interactive multimedia video blood/plasma donor health history system in operational settings. They will be achieved by progressive integration of the system into the donation and data management process and by stepwise increases in sophistication of the system. Benefits anticipated are improvement in: 1. overall performance of operational systems for screening blood/plasma donors and collecting blood products, and 2. the safety of blood and plasma supplies. Achievements will be attained in stages beginning with updating, testing and installation of Talisman's 1993 pilot tested stand-alone system. The Talisman multimedia system acquired the first ever marketing clearance from regulators on 12/5/97. Development will proceed according to the plan for SBIR Phase Il to be constructed based on cost-benefit analyses during Phase l. The tentative end point objective for Phase Il is a paperless collection system and enhanced functionality for the screening system. Other parts of the plan will address measures of benefits and costs and development of a production regulatory compliant Quality System. When completed the system will address up to 40% of blood banking costs and 60% of reportable errors. PROPOSED COMMERCIAL APPLICATIONS: With over 25,000,000 annual US blood and plasma donations, and three or four times this market world wide, depending on how potential implementers value benefits, the system could be worth tens of millions of dollars. If the system were successful in preventing just one donation that ultimately resulted in a product recall from entering a plasma pool, the value to the manufacturer could be in excess of $1,000,000.